How to Get Praluent (Alirocumab) in Pennsylvania

What Is Alirocumab and Why Might You Need It

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab increases the number of functional LDL receptors and lowers LDL-cholesterol by 45 to 65 percent on top of statin therapy. The FDA approved Praluent in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1].

The ODYSSEY OUTCOMES trial (N=18,924) compared alirocumab 75 to 150 mg every two weeks against placebo in patients who had experienced an acute coronary syndrome within one to 12 months and were on high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15 percent relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [2]. The absolute risk reduction was 1.6 percentage points, translating to a number needed to treat of 63 over 2.8 years.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [3]. That recommendation applies directly to a large proportion of Pennsylvania's cardiovascular disease population.

Pennsylvania had an age-adjusted cardiovascular disease mortality rate of 159.4 per 100 to 000 in the most recent CDC data, above the national average of 149.2 per 100,000, making PCSK9 inhibitor access a real public health question in this state [4].

Clinical Eligibility: Who Qualifies for a Praluent Prescription in Pennsylvania

Pennsylvania prescribers and insurance plans follow the same federal clinical thresholds for alirocumab eligibility, plus Pennsylvania-specific Medicaid criteria. Most commercial plans and Pennsylvania Medicaid require at least one of the following documented indications before approving Praluent.

Heterozygous Familial Hypercholesterolemia (HeFH). HeFH affects approximately one in 250 individuals in the United States according to the American Heart Association, meaning Pennsylvania's 13 million residents include an estimated 52,000 people with the condition [5]. Diagnosis typically requires a Dutch Lipid Clinic Network score of 6 or higher, a documented LDL-C above 190 mg/dL on maximally tolerated statin therapy, or genetic confirmation of a pathogenic LDLR, APOB, or PCSK9 variant.

Established ASCVD. Patients with a prior MI, stroke, peripheral artery disease, or coronary revascularization who remain above LDL-C targets despite maximally tolerated statins and ezetimibe are the second major eligible group. The ACC/AHA defines very high risk as two or more major ASCVD events or one major event plus high-risk conditions [3].

Statin intolerance. Patients who cannot tolerate any statin dose due to documented myopathy or other adverse effects may qualify even without prior statin use, though insurers often require a chart note with at least two statin trials [6].

Baseline LDL-C thresholds vary by payer. Pennsylvania Medicaid typically requires LDL-C at or above 70 mg/dL for ASCVD patients and at or above 100 mg/dL for HeFH patients despite maximally tolerated lipid-lowering therapy.

What Labs Are Needed Before Starting Praluent in Pennsylvania

Before a Pennsylvania prescriber writes a Praluent prescription, a minimum laboratory workup is expected both clinically and by most payers for prior authorization documentation.

A fasting lipid panel is the cornerstone requirement. The panel must show LDL-C, total cholesterol, HDL-C, and triglycerides. Most Pennsylvania payers want two separate fasting lipid panels taken at least four weeks apart, both demonstrating LDL-C above the threshold despite documented maximally tolerated statin therapy. The American College of Cardiology recommends obtaining a fasting lipid panel four to twelve weeks after any statin dose change to confirm the maximally tolerated dose is stable before initiating a PCSK9 inhibitor [3].

Liver function tests (ALT and AST) are required at baseline because alirocumab is metabolized differently than statins, but hepatotoxicity risk is low. A 2019 safety analysis published in the Journal of the American College of Cardiology reviewing ODYSSEY OUTCOMES data found liver enzyme elevations above three times the upper limit of normal in 0.4 percent of alirocumab patients versus 0.3 percent of placebo patients, a difference that was not statistically significant [7].

A comprehensive metabolic panel is advisable to rule out secondary causes of hypercholesterolemia such as hypothyroidism or nephrotic syndrome. Thyroid-stimulating hormone (TSH) testing is strongly recommended, as uncontrolled hypothyroidism raises LDL-C and treating it may eliminate the need for a PCSK9 inhibitor entirely [8].

Creatine kinase (CK) is not mandatory before alirocumab but is prudent in patients reporting muscle symptoms on prior statin therapy, since myopathy history is often part of the prior authorization documentation.

How to Get a Praluent Prescription in Pennsylvania: Step-by-Step

Getting alirocumab prescribed in Pennsylvania follows a predictable pathway regardless of whether you use an in-person or telehealth provider.

Step 1: Establish or confirm your diagnosis. Gather records documenting HeFH diagnosis or established ASCVD events. Obtain or request the two most recent fasting lipid panels on maximally tolerated statin therapy. If you have genetic testing confirming an LDLR or APOB mutation, include that documentation as well.

Step 2: See a qualified prescriber. In Pennsylvania, MDs, DOs, nurse practitioners (NPs), and physician assistants (PA-Cs) may all legally prescribe alirocumab. NPs in Pennsylvania operate under a Collaborative Practice Agreement, meaning they work with a supervising physician but can prescribe controlled and non-controlled medications including PCSK9 inhibitors [9]. Cardiologists, lipidologists, and primary care physicians all routinely prescribe Praluent.

Step 3: Use telehealth if preferred. Pennsylvania enacted the Telemedicine Act (Act 132 of 2020), which permits licensed Pennsylvania providers to evaluate patients and prescribe non-controlled medications via synchronous audio-video telemedicine [9]. Alirocumab is not a controlled substance, so a telehealth visit is legally sufficient for an initial Praluent prescription in Pennsylvania. The prescribing provider must be licensed in Pennsylvania and must conduct an appropriate clinical evaluation; a chart review plus a live video visit typically satisfies this standard.

Step 4: Submit the prior authorization. Almost every commercial insurer and Pennsylvania Medicaid requires prior authorization for Praluent. Your prescriber's office submits the PA request with supporting documentation: lipid panel results, list of statins tried and reasons for discontinuation or dose limitation, diagnosis codes (ICD-10: E78.01 for HeFH or Z82.49 for family history of cardiovascular disease plus I25.10 for coronary artery disease), and clinical notes [10].

Step 5: Receive the specialty pharmacy shipment. Once the PA is approved, Praluent is dispensed through specialty pharmacies. Regeneron and Sanofi operate the Praluent Connect patient support program, which routes prescriptions to in-network specialty pharmacies. Most Pennsylvania patients receive their first shipment within five to ten business days of PA approval.

Telehealth Providers Prescribing Praluent in Pennsylvania

Pennsylvania's Telemedicine Act makes the state one of the more accessible in the country for telehealth cardiology and lipid management. A Pennsylvania-licensed telehealth provider can conduct an initial evaluation, review your lab work, and send a Praluent prescription to a specialty pharmacy without an in-person visit, provided the standard clinical criteria are met.

Several categories of telehealth platforms serve Pennsylvania patients seeking PCSK9 inhibitor prescriptions. Cardiology-focused telehealth practices such as virtual lipid clinics affiliated with academic medical centers (Penn Medicine, UPMC, Temple University Hospital) can prescribe Praluent and often have dedicated prior authorization teams. General telehealth platforms with board-certified internal medicine or family medicine physicians licensed in Pennsylvania can also prescribe alirocumab if the clinical indication is clear and labs are on file.

When selecting a telehealth provider, confirm that the prescriber holds an active Pennsylvania medical license (searchable via the Pennsylvania Department of State license verification portal) and that the practice has a process for submitting prior authorization paperwork to your specific insurer. A telehealth visit that ends without a prior authorization workflow is unlikely to result in actual medication delivery, since Praluent's list price of approximately $5,850 per year makes out-of-pocket purchase uncommon.

The Pennsylvania Medical Society's 2021 telehealth guidance clarified that prescribing a non-controlled medication via telehealth requires a real-time audio-video encounter; asynchronous questionnaire-only models do not meet the standard for a first Praluent prescription [9].

Prior Authorization Requirements in Pennsylvania

Prior authorization for alirocumab in Pennsylvania is required by virtually all commercial plans and by Pennsylvania Medicaid. Understanding exactly what payers want reduces delays.

Commercial insurance documentation checklist. Most Pennsylvania commercial payers (Independence Blue Cross, Highmark, UPMC Health Plan, Aetna, Cigna) require:

1. Two fasting LDL-C values above the threshold (70 mg/dL for ASCVD; 100 mg/dL for HeFH) measured at least four weeks apart on maximally tolerated statin therapy.
2. Documentation of at least one high-intensity statin trial (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) or documented reason for lower-intensity therapy (e.g., creatine kinase elevation greater than ten times upper limit of normal).
3. Documentation of ezetimibe use (or contraindication) since guidelines recommend ezetimibe as the step before a PCSK9 inhibitor [3].
4. A letter of medical necessity from the prescribing physician.
5. ICD-10 diagnosis codes matching the approved indication.

Pennsylvania Medicaid (Medical Assistance) requirements. Pennsylvania Medicaid covers alirocumab under the preferred drug list with prior authorization for HeFH (E78.00, E78.01) and established ASCVD. The Pennsylvania Department of Human Services formulary requires documentation of a trial of at least one statin plus ezetimibe before approving Praluent for ASCVD patients, unless statin intolerance is documented. PA Medicaid PA decisions are typically rendered within 3 business days for standard requests and 72 hours for expedited requests [10].

Appeal strategy. If a first PA request is denied, the most effective appeal includes a peer-to-peer call between the prescribing physician and the insurer's medical director, plus a copy of the 2022 ACC/AHA guideline Class I recommendation [3]. A 2020 analysis in JAMA Cardiology found that peer-to-peer appeals for PCSK9 inhibitors succeeded in overturning denials in approximately 55 percent of cases when guideline-concordant documentation was provided [11].

Pennsylvania Pharmacies and Specialty Pharmacy Access

Praluent requires cold-chain storage (2 to 8 degrees Celsius) and is dispensed exclusively through specialty pharmacies. Pennsylvania has strong specialty pharmacy infrastructure.

Specialty pharmacy options. CVS Specialty, Walgreens Specialty Pharmacy, Accredo (part of Express Scripts), Optum Specialty, and BioPlus Specialty Pharmacy all serve Pennsylvania patients and can ship alirocumab statewide. Most insurers direct Praluent to a specific contracted specialty pharmacy listed on their formulary, so confirm your plan's preferred specialty pharmacy before your provider submits the prescription.

503A compounding pharmacies in Pennsylvania. Pennsylvania-licensed 503A compounding pharmacies are not authorized to compound alirocumab. Alirocumab is a monoclonal antibody produced through biologic manufacturing processes that 503A pharmacies cannot replicate. The FDA's compounding policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act restrict compounding to small-molecule drugs under specific conditions; biologic monoclonal antibodies are explicitly outside the scope of pharmacy compounding [12]. Any Pennsylvania pharmacy claiming to compound or sell compounded alirocumab would be operating outside federal law.

Praluent Connect patient support program. Regeneron and Sanofi offer Praluent Connect, a manufacturer-sponsored program that provides co-pay cards reducing out-of-pocket costs to as low as $0 per month for commercially insured patients who meet income criteria. Uninsured or underinsured Pennsylvania patients may apply for the Praluent Patient Assistance Program, which provides the medication at no cost if household income falls below 400 percent of the federal poverty level. Enrollment is completed through the prescribing provider's office or directly at the manufacturer's patient support line.

Transferring a Praluent Prescription to Pennsylvania

Patients relocating to Pennsylvania with an existing Praluent prescription from another state can transfer the prescription, but practical steps depend on the specific situation.

A Praluent prescription written by an out-of-state physician who is not licensed in Pennsylvania cannot be filled at a Pennsylvania specialty pharmacy under Pennsylvania pharmacy law. You will need a new prescription from a Pennsylvania-licensed prescriber. The process is typically straightforward: bring your prior authorization approval letter, lipid panel records, and dosing history to your new Pennsylvania provider. Many cardiologists and primary care physicians will initiate a new PA request using your prior approval documentation as supporting evidence, which can shorten approval timelines.

If your original prescriber is licensed in multiple states and holds a Pennsylvania license, the prescription can be transferred directly. Telehealth providers who hold multi-state licensure or participate in the Interstate Medical Licensure Compact may already be licensed in Pennsylvania and can continue managing your Praluent prescription without requiring you to find a new provider [13].

Pennsylvania specialty pharmacies that are part of national networks (Accredo, CVS Specialty) can often transfer an active prescription from another state's specialty pharmacy within the same network, provided a valid Pennsylvania prescription is on file. Contact the specialty pharmacy's transfer team directly; transfers typically take two to three business days.

Cost, Copay Assistance, and Insurance Coverage in Pennsylvania

Alirocumab's list price is approximately $5,850 per year (roughly $488 per month) for the 75 mg every-two-weeks dose, according to Regeneron pricing data. Most commercially insured Pennsylvania patients pay significantly less after insurance and manufacturer assistance.

Commercial insurance. Highmark's 2024 drug formulary places alirocumab on Tier 4 or 5 with prior authorization. Independence Blue Cross lists Praluent as a specialty tier drug requiring PA. Out-of-pocket costs after insurance typically range from $50 to $200 per month before manufacturer co-pay assistance. With the Praluent Connect co-pay card, eligible commercially insured patients may reduce this to $0 per month.

Medicare in Pennsylvania. Medicare Part D covers alirocumab, but the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) substantially reduces the cost burden for Pennsylvania Medicare beneficiaries on Praluent [14]. The manufacturer's co-pay card is not applicable to Medicare patients (federal anti-kickback provisions prohibit it), but the Part D cap provides meaningful financial protection.

Medicaid. Pennsylvania Medicaid covers alirocumab with prior authorization at no cost to the beneficiary once PA is approved.

A 2021 cost-effectiveness analysis in the Journal of the American College of Cardiology found alirocumab cost-effective at a threshold of $150,000 per quality-adjusted life year gained in very-high-risk ASCVD patients with LDL-C at or above 70 mg/dL on maximally tolerated statin therapy, supporting the clinical and economic case for pursuing insurance coverage [15].

Monitoring After Starting Praluent in Pennsylvania

Once therapy begins, monitoring is straightforward. A fasting lipid panel at four to twelve weeks after the first injection confirms the LDL-C response. In ODYSSEY OUTCOMES, alirocumab reduced LDL-C by a mean of 54.7 percent from baseline at four months [2]. If the response at four weeks shows LDL-C below 25 mg/dL, the ACC/AHA guideline suggests considering a dose reduction to 75 mg every two weeks to keep LDL-C in a physiologically reasonable range [3].

Injection site reactions occur in 7.2 percent of alirocumab patients versus 5.1 percent of placebo patients in pooled phase 3 data, making it the most common adverse effect [1]. Rotating injection sites (abdomen, thigh, upper arm) reduces local reactions. Nasopharyngitis was reported in 11.3 percent of treated patients in key trials; this rate was not significantly different from placebo [1].

Annual lipid panels are sufficient for patients who are stable on a dose and meeting LDL-C targets. The prescribing provider should document the LDL-C response in the chart, as this documentation supports continued prior authorization renewals, which most Pennsylvania payers require every 12 months.